Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294086 · ClinicalTrials.gov registry record · Phase 2
A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00294086 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 160 participants.
The verdict
NCT00294086, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This study will evaluate the tolerability and safety of valsartan in patients with stable, chronic heart failure (NYHA Class ll-lll). The 12-week double blind study has a 2-week (maximum) screening, and a 10-week active treatment phase. In each of the treatment arms (QD and BID), patients are up-titrated to a maximum valsartan total daily dose of 320 mg. Patients remain on their prior CHF standard care therapy throughout the study period, and the up-titration of valsartan is based on patient tolerability.
Interventions
- DRUG valsartan 160 mg
- DRUG valsartan 160 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294086
The ClinicalTrials.gov registry entry for NCT00294086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which valsartan 160 mg is the first listed.
NCT00294086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00294086 about?
NCT00294086 is a clinical study titled "A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure". This study will evaluate the tolerability and safety of valsartan in patients with stable, chronic heart failure (NYHA Class ll-lll). The 12-week double blind study has a 2-week (maximum) screening, and a 10-week active treatment phase. In each of the treatment arms (QD and BID), patients are up-tit...
What is the current status of trial NCT00294086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2005-12. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00294086?
The interventions under investigation include: valsartan 160 mg (DRUG), valsartan 160 mg BID (DRUG).
Who is sponsoring clinical trial NCT00294086?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.